HighTower Advisors
ALXN

HighTower Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

HighTower Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$1K – 2394
2017
Q2 		$1K Buy
+200
New +$23.3K ﹤0.01% 2208

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

HighTower Advisors's ALXN Position: Q3 2021 in Review

HighTower Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 16,974 shares — an estimated $3.13M sold.

HighTower Advisors first reported a position in ALXN in Q4 2013 and held it in 29 quarters. The position peaked at $5.81M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • HighTower Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • HighTower Advisors sold 16,974 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.13M.
  • HighTower Advisors first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 29 quarters.
  • HighTower Advisors's Alexion Pharmaceuticals position peaked at $5.81M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on HighTower Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.